Related Experiment Video
Updated: Aug 4, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
38.9K
Generalized pustular psoriasis successfully treated with spesolimab: A case report
Noemi Brigenti1, Paolo Gisondi1, Francesco Bellinato1
1Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy.
SAGE Open Medical Case Reports
|February 29, 2024
Summary
Generalized pustular psoriasis (GPP) is a severe skin condition. Spesolimab, an IL-36 receptor antagonist, achieved rapid, complete, and durable remission in a GPP patient resistant to other treatments.
Area of Science:
- Dermatology
- Immunology
- Rare Diseases
Background:
- Generalized pustular psoriasis (GPP) is a severe, rare inflammatory skin disease characterized by sterile pustules.
- GPP can present with or without systemic inflammation and may coexist with psoriasis vulgaris.
- Treatment for GPP is often challenging, with many patients exhibiting resistance to conventional and biologic therapies.
Observation:
- A 48-year-old female patient with a 15-year history of severe GPP and plaque psoriasis was treated.
- The patient had previously shown resistance to multiple treatment regimens, including conventional and biologic agents.
- Spesolimab, a monoclonal antibody targeting the interleukin-36 receptor, was administered.
Findings:
- Spesolimab treatment resulted in a rapid and complete clinical remission of GPP symptoms.
- The remission achieved with spesolimab was durable, lasting up to 12 months post-treatment.
- This case highlights the efficacy of IL-36 pathway inhibition in refractory GPP.
Implications:
- Spesolimab represents a promising therapeutic option for patients with severe generalized pustular psoriasis.
- Targeting the IL-36 receptor may be a key strategy for managing difficult-to-treat GPP.
- Further research into IL-36 antagonism is warranted for GPP and related autoinflammatory conditions.
